Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes
Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes
New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.
The SRFF team was led by Partner Jeffrey J. Fessler.
- Sichenzia Ross Ference LLP代表Biosolar，Inc.进行500万美元的注册直接发行 - April 7, 2021
- Sichenzia Ross Ference LLP代表SeaChange International，Inc.进行1,910万美元的普通股公开发行 - April 5, 2021
- Sichenzia Ross Ference LLP代表Vuzix Corporation进行9,750万美元的普通股公开发行 - April 1, 2021